Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;49(1):79-93.
doi: 10.1016/j.ecl.2019.11.002.

Diabetes Technology in the Inpatient Setting for Management of Hyperglycemia

Affiliations
Review

Diabetes Technology in the Inpatient Setting for Management of Hyperglycemia

Georgia M Davis et al. Endocrinol Metab Clin North Am. 2020 Mar.

Abstract

In past decades, a rapid evolution of diabetes technology led to increased popularity and use of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) in the ambulatory setting for diabetes management, and recently, the artificial pancreas became available. Efforts to translate this technology to the hospital setting have shown accuracy and reliability of CGM, safety of CSII in appropriate populations, improvement of inpatient glycemic control with computerized glycemic management systems, and feasibility of inpatient CGM-CSII closed-loop systems. Several ongoing studies are focusing on continued translation of this technology to improve glycemic control and outcomes in hospitalized patients.

Keywords: Diabetes; Glycemic control; Hospital; Inpatient; Technology.

PubMed Disclaimer

Conflict of interest statement

Disclosure G.M. Davis and A.L. Migdal have no disclosures. R.J. Galindo is partly supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number P30DK11102. R.J. Galindo has received research grant support to Emory University for investigator-initiated studies from Novo Nordisk, and consulting fees from Abbott Diabetes Care, Sanofi, Valeritas, and Novo Nordisk. G.E. Umpierrez is partly supported by research grants from the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378 from the Clinical and Translational Science Award program and a National Institutes of Health (NIH) grant U30, P30DK11102, and has received research grant support to Emory University for investigator-initiated studies from Sanofi, Novo Nordisk, and Dexcom.

Figures

Fig. 1.
Fig. 1.
Algorithm for inpatient continuation of CSII-CGM therapy hospitalization. EGD, upper endoscopy; IV, intravenous. (From Umpierrez GE, Klonoff DC. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care. 2018;41(8):1579–1589; with permission.)

References

    1. Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care 2018;41(8): 1579–89. - PMC - PubMed
    1. Wallia A, Umpierrez GE, Rushakoff RJ, et al. Consensus statement on inpatient use of continuous glucose monitoring. J Diabetes Sci Technol 2017;11(5): 1036–44. - PMC - PubMed
    1. Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101(11):3922–37. - PubMed
    1. Fonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: a consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract 2016;22(8):1008–21. - PubMed
    1. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract 2014;20(5):463–89. - PubMed

Publication types

MeSH terms